InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,153.92
(
-1.67%
)
Post# of 253511
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: jq1234 post# 170487

Monday, 11/25/2013 2:06:29 PM

Monday, November 25, 2013 2:06:29 PM

Post# of 253511

CBST/CXA201 in cUTI: It is actually superior to levofloxacin even though it is a non-inferiority trial, 95% CI = 2.3%, 14.6%.

Indeed plus AE were similar.

Result from another ph3 in cIAI will be in late Dec.

It is also being developed for hospital-acquired bacterial pneumonia, which should be even a bigger market. That strengthen my view that CXA-201 is quite important for CBST more than anti MRSA agents (#msg-64341997).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up